| Drug General Information |
| Drug ID |
D03MDW
|
| Former ID |
DNCL003433
|
| Drug Name |
DS-7309
|
| Indication |
Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1]
|
Phase 1 |
[1]
|
|---|
| Company |
Daiichi Sankyo
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Target and Pathway |
| Target(s) |
Glucokinase |
Target Info |
Inhibitor |
[2]
|
|---|
|
KEGG Pathway
|
Glycolysis / Gluconeogenesis
|
|
Galactose metabolism
|
|
Starch and sucrose metabolism
|
|
Amino sugar and nucleotide sugar metabolism
|
|
Butirosin and neomycin biosynthesis
|
|
Metabolic pathways
|
|
Biosynthesis of antibiotics
|
|
Carbon metabolism
|
|
Insulin signaling pathway
|
|
Insulin secretion
|
|
Prolactin signaling pathway
|
|
Glucagon signaling pathway
|
|
Type II diabetes mellitus
|
|
Maturity onset diabetes of the young
|
|
Central carbon metabolism in cancer
|
|
Pathway Interaction Database
|
FOXA2 and FOXA3 transcription factor networks
|
|
HIF-1-alpha transcription factor network
|
|
PathWhiz Pathway
|
Nucleotide Sugars Metabolism
|
|
Starch and Sucrose Metabolism
|
|
Galactose Metabolism
|
|
Trehalose Degradation
|
|
Reactome
|
Regulation of gene expression in beta cells
|
|
Glucose transport
|
|
Glycolysis
|
|
WikiPathways
|
SIDS Susceptibility Pathways
|
|
Glycolysis and Gluconeogenesis
|
|
MAPK Signaling Pathway
|
|
Regulation of beta-cell development
|
|
Metabolism of carbohydrates
|
|
Hexose transport
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01956305) Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study. U.S. National Institutes of Health. |
|---|
| REF 2 | Glucokinase alternative. SciBX 6(45); doi:10.1038/scibx.2013.1279. Nov. 21 2013 |
|---|
